Sanofi $SNY Stock Position Lifted by Steward Partners Investment Advisory LLC

Steward Partners Investment Advisory LLC grew its position in Sanofi (NASDAQ:SNY) by 5.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 67,028 shares of the company’s stock after acquiring an additional 3,600 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Sanofi were worth $3,238,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in SNY. Ameritas Advisory Services LLC bought a new stake in Sanofi during the second quarter valued at $28,000. Accent Capital Management LLC bought a new position in shares of Sanofi in the 1st quarter worth about $29,000. Eastern Bank boosted its holdings in shares of Sanofi by 121.0% in the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after buying an additional 300 shares during the period. Banque Transatlantique SA bought a new stake in shares of Sanofi during the 1st quarter valued at about $33,000. Finally, Brentview Investment Management LLC acquired a new stake in Sanofi during the first quarter worth about $42,000. 14.03% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

SNY has been the subject of a number of research reports. Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $56.00 to $58.00 in a research note on Monday, September 8th. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Weiss Ratings restated a “hold (c+)” rating on shares of Sanofi in a research note on Monday. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Finally, Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a research report on Monday, October 27th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $62.67.

Sanofi Stock Down 0.5%

Shares of Sanofi stock opened at $50.03 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.06 and a quick ratio of 0.94. Sanofi has a 1-year low of $44.62 and a 1-year high of $60.12. The business’s fifty day moving average price is $49.51 and its two-hundred day moving average price is $49.26. The company has a market capitalization of $122.85 billion, a P/E ratio of 11.72, a PEG ratio of 1.38 and a beta of 0.49.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Friday, October 24th. The company reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $1.31. The company had revenue of $15.46 billion for the quarter, compared to analyst estimates of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The company’s quarterly revenue was down 7.5% compared to the same quarter last year. During the same period last year, the company earned $2.25 earnings per share. As a group, research analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.